1stOncology™: Cancer Intelligence Service – Page 15939 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017

On November 16, 2017 Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, reported that Michael Mulroy, President and Chief Executive Officer, will present at the Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel in New York City (Press release, BioTime, NOV 16, 2017, View Source;p=RssLanding&cat=news&id=2317554 [SID1234522118]). Asterias’ presentation is scheduled for Tuesday, November 28, 2017, at 12:30 p.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible at View Source An archived presentation will be available for 90 days after the event.

BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference

On November 16, 2017 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 29th Annual Piper Jaffray Healthcare Conference in New York on November 28, 2017 at 3:00 p.m. Eastern Time (Press release, BioCryst Pharmaceuticalsa, NOV 16, 2017, View Source [SID1234522103]).

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at View Source

BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York

On November 16, 2017 BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, reported that it will host an investor breakfast meeting on Tuesday, December 5, 2017 at the Convene Conference Center near Grand Central in New York, NY (Press release, BioLineRx, NOV 16, 2017, View Source;p=RssLanding&cat=news&id=2317384 [SID1234522104]).

The agenda and topics for discussion include: (i) a keynote presentation by Dr. John F. DiPersio, Chief, Division of Oncology at Washington University School of Medicine, on bone marrow transplantation and the role of CXCR4 in cancer; (ii) presentation on BL-8040 development plans in immuno-oncology combinations, as well as on the upcoming GENESIS Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation in multiple myeloma patients; (iii) presentation of AGI-134, the Company’s novel immuno-oncology project; and (iv) an overview of the Company’s plans and expected milestones for 2018.

The investor meeting schedule is as follows:

8:30 am EST – Registration
9:00-10:30 am EST – Formal Presentations and Q&A
Location:

Convene Conference Center
101 Park Avenue near Grand Central
New York, NY
888-730-7307

BioLineRx Ltd. will also host a live audio webcast of the investor breakfast. To access the webcast, please go to the breakfast event page on BioLineRx’s website. It is recommended that users register 15 minutes prior to the scheduled start time to ensure timely connection. An audio replay of the meeting will also be available for approximately three months following the meeting on the breakfast event page.

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)

On September 16, 2017 Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, reported that data from the Phase 2 trial of SL-701 in patients with second-line glioblastoma (GBM) were selected for oral presentation at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO) being held November 16-19, 2017 in San Francisco, CA (Press release, Stemline Therapeutics, NOV 16, 2017, View Source [SID1234522107]).

David A. Reardon, M.D., lead investigator of the study and presenting author, commented, "SL-701 is exhibiting very encouraging clinical activity, including long-term survivors, as both a single agent and in combination with bevacizumab in a relapsed GBM patient population. Notably, we are also witnessing evidence of a robust target-specific CD8+ T-cell response tracking with clinical benefit – a very exciting development and confirmation of the drug’s immune mechanism of action. Given the positive results seen here, combined with a high unmet medical need in GBM, I will be working closely with Stemline to develop a rational, registrational path forward for SL-701."

Details on the presentation are as follows:

Title:
Phase 2 Trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and survivin, in adults with second-line recurrent GBM
Presenter: David Reardon, MD; Dana-Farber Cancer Institute
Abstract: ATIM-10
Date/Time: Sunday, November 19, 2017 – 10:45-10:55 AM PT

A copy of the oral presentation will be available on the Stemline website (www.stemline.com), under the Scientific Presentations tab, following the SNO presentation.

Akebia Therapeutics to Participate in Upcoming Investor Conferences

On November 16, 2017 Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), reported that John P. Butler, President and Chief Executive Officer, will participate in the following investor conferences(Press release, Akebia, NOV 16, 2017, View Source [SID1234522110]):

The 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017, at 12:30 p.m. Eastern Time, to be held at the Lotte New York Palace in New York, NY.
The Evercore ISI Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017, at 9:30 a.m. Eastern Time, to be held at the Boston Harbor Hotel in Boston, MA.
The Global Mizuho Investor Conference on Tuesday, December 5, 2017, to be held at the Lotte New York Palace in New York, NY.
A live audio webcast from the presentation at Piper Jaffray and fireside chat at Evercore will be available on the Company’s website at View Source, with archives available for 90 days.